Sirolimus and liver transplantation: Clinical implications for hepatocellular carcinoma

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 9, 2007, Pages 1275-1282

  Campsen, Jeffrey ^a   Zimmerman, Michael A ^a   Trotter, James F ^a   Wachs, Michael ^a   Bak, Thomas ^a   Mandell, Susan ^a   Kam, Igal ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Hepatic artery thrombosis; Hepatocellular carcinoma; Liver transplant; Sirolimus

Indexed keywords

ACETYLSALICYLIC ACID; CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; VASCULOTROPIN; IMMUNOSUPPRESSIVE AGENT;

ADENOCARCINOMA; ANEMIA; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MOUTH ULCER; NEUROLOGIC DISEASE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; REVIEW; RODENT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT INDICATION; LIVER TUMOR;

CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; SIROLIMUS;

EID: 34250835612     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.9.1275     Document Type: Review

References (44)

1. NEUHAUS P, KLUPP J, LANGREHR JM: mTOR inhibitors: an overview. Liver Transpl. (2001) 7(6):473-484.
2. TROTTER JF: Sirolimus in liver transplantation. Transplant Proc. (2003) 35(3 Suppl.):193S-200S.
3. KAHAN BD: Cyclosporin A, FK506, rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions. J. Am. Soc. Nephrol. (1992) 2(12 Suppl):S222-S227.
4. GUBA M, VON BREITENBUCH P, STEINBAUER M et al.: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. (2002) 8(2):128-135.
5. LUAN FL, HOJO M, MALUCCIO M, YAMAJI K, SUTHANTHIRAN M: Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation (2002) 73(10):1565-1572.
6. WATSON CJ, FRIEND PJ, JAMIESON NV et al.: Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation (1999) 67(4):505-509.
7. CHANG GJ, MAHANTY HD, QUAN D et al.: Experience with the use of sirolimus in liver transplantation - use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl. (2000) 6(6):734-740.
8. NEFF GW, MONTALBANO M, SLAPAK-GREEN G et al.: Sirolimus therapy in orchotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc. (2003) 35(8):3029-3031.
9. MCALISTER VC, PELTEKIAN KM, MALATJALIAN DA et al.: Orthoropic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl. (2001) 7(8):701-708.
10. TROTTER JF, WACHS M, BAK T et al.: Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl. (2001) 7(4):343-351.
11. DUNKELBERG JC, TROTTER JF, WACHS M et al.: Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. (2003) 9(5):463-468.
12. ZAGHLA H, SELBY RR, CHAN LS et al.: A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol. Ther. (2006) 23(4):513-520.
13. CHOI SB: CYPHER coronary stents and risk of thrombosis. CMAJ (2003) 169(3):218.
14. PRIDOHL O, HEINEMANN K, HARTWIG T et al.: Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results. Transplant Proc. (2001) 33(7-8):3229-3231.
15. WEISNER R, KLINTMALM G, McDIARMID & RAPAMUNE LIVER TRANSPLANT STUDY GROUP: Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients. Am. J. Transplant (2002) 2:464 (abstract).
16. KNIEPEISS D, IBERER F, GRASSER B, SCHAFFELLNER S, TSCHELIESSNIGG KH: Sirolimus and mycophenolate mofetil after liver transplantation. Tanspl. Int. (2003) 16(7):504-509.
17. NEFF GW, MONTALBANO M, TZAKIS AG: Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc. (2003) 35(3 Suppl):209S-216S.
18. FORGACS B, MERHAV HJ, LAPPIN J, MIELES L: Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc. (2005) 37(4):1912-1914.
19. FAIRBANKS KD, EUSTACE JA, FINE D, THULUVATH PJ: Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl. (2003) 9(10):1079-1085.
20. NAIR S, EASON J, LOSS G: Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl. (2003) 9(2):126-129.
21. LAM P, YOSHIDA A, BROWN K et al.: The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig. Dis. Sci. (2004) 49(6):1029-1035.
22. SANCHEZ EQ, MARTIN AP, IKEGAMI T et al.: Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc. (2005) 37(10):4416-4423.
23. BACKMAN L, REISAETER AV, WRAMNER L et al.: Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus. Clin. Transplant (2006) 20(3):336-339.
24. ZIMMERMAN M, BUSUTTIL RW: Long-term efficacy of percutaneous thermal ablation for patients with recurrent hepatocellular carcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. (2006) 3(5):250-251.
25. HOJO M, MORIMOTO T, MALUCCIO M et al.: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 397(6719):530-534.
26. FREISE CE, FERRELL L, LIU T, ASCHER NL, ROBERTS JP: Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation (1999) 67(4):510-513.
27. PRICE DJ, GROVE JR, CALVO V, AVRUCH J, BIERER BE: Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science (1992) 257(5072):973-977.
28. SAHIN F, KANNANGAI R, ADEGBOLA O et al.: mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res. (2004) 10(24):8421-8425.
29. RIZELL M, LINDNER P: Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res. (2005) 25(2A):789-793.
30. SCHUMACHER G, OIDTMANN M, RUEGGEBERG A et al.: Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J. Gastroenterol. (2005) 11(10):1420-1425.
31. GUBA M, KOEHL GE, NEPPL E et al.: Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl. Int. (2005) 18(1):89-94.
32. GUBA M, YEZHELYEV M, EICHHORN ME et al.: Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood (2005) 105(11):4463-4469.
33. STIPPEL DL, KASPER HU, SCHLEIMER K et al.: Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc. (2005) 37(5):2185-2187.
34. ELSHARKAWI M, STAIB L, HENNE-BRUNS D, MAYER J: Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation (2005) 79(7):855-857.
35. VIVARELLI M, BELLUSCI R, CUCCHETTI A et al.: Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation (2002) 74(12):1746-1751.
36. VIVARELLI M, CUCCHETTI A, PISCAGLIA F et al.: Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl. (2005) 11(5):497-503.
37. KNETEMAN NM, OBERHOLZER J, AL SAGHIER M et al.: Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. (2004) 10:1301-1311.
38. ZHOU J, FAN J, WANG Z et al.: Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World J. Gastroenterol. (2006) 12(19):3114-3118.
39. SAIGAL S, NORRIS S, MUIESAN P et al.: Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl. (2002) 8(5):482-487.
40. NABEL GJ: A transformed view of cyclosporine. Nature (1999) 397(6719):471-472.
41. SHAPIRO R, YOUNG JB, MILFORD EL et al.: Immunosuppression: evolution in practice and trends, 1993-2003. Am. J. Transplant (2005) 5(4 Pt 2):874-886.
42. EISEN HJ, TUZCU EM, DORENT R et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. (2003) 349(9):847-858.
43. VITKO S, MARGREITER R, WEIMAR W et al.: Everolimus (Certican) 12-month safety and efficacy versus mycophenolate moferil in de novo renal transplant recipients. Transplantation (2004) 78 (10):1532-1540.
44. LEVY G, SCHMIDLI H, PUNCH J et al.: Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. (2006) 12(11):1640-1648.